Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies

J. A. Oyer, X. Huang, Y. Zheng, J. Shim, T. Ezponda, Z. Carpenter, M. Allegretta, C. I. Okot-Kotber, J. P. Patel, A. Melnick, R. L. Levine, A. Ferrando, A. D. MacKerell, Neil L Kelleher, J. D. Licht, R. Popovic

Research output: Contribution to journalLetter

69 Scopus citations
Original languageEnglish (US)
Pages (from-to)198-201
Number of pages4
JournalLeukemia
Volume28
Issue number1
DOIs
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Oyer, J. A., Huang, X., Zheng, Y., Shim, J., Ezponda, T., Carpenter, Z., Allegretta, M., Okot-Kotber, C. I., Patel, J. P., Melnick, A., Levine, R. L., Ferrando, A., MacKerell, A. D., Kelleher, N. L., Licht, J. D., & Popovic, R. (2014). Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia, 28(1), 198-201. https://doi.org/10.1038/leu.2013.204